Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan

TARRYTOWN, N.Y. and PARIS, July 5, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Praluent® (alirocumab) for the treatment of uncontrolled low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia at high cardiovascular risk.

Praluent is a human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). In Japan, Praluent is indicated for the treatment of patients with hypercholesterolemia and familial hypercholesterolemia (FH) who are at high cardiovascular risk and in whom treatment with statins (HMG-CoA reductase inhibitors) is not sufficient. Praluent 75 mg and 150 mg will be available in Japan as a single-dose pre-filled pen and syringe.

“Hypercholesterolemia is a significant concern in Japan, and many patients are not able to achieve their LDL cholesterol treatment goals despite current lipid-lowering therapy,” said Jay Edelberg, MD, Ph.D., Head of Cardiovascular Development, Sanofi. “For these patients, Praluent could be an important treatment option to help address their needs.”

Data from the global Phase 3 ODYSSEY trials showed consistent, robust reductions in LDL cholesterol for Praluent compared to placebo, when added to current standard-of-care, which included maximally-tolerated statins. The Phase 3 ODYSSEY JAPAN trial evaluated the safety and efficacy of Praluent 75 mg starting dose every two weeks, in comparison with placebo in 216 Japanese patients with primary hypercholesterolemia and LDL cholesterol of at least 100 milligrams/deciliter (mg/dL) (at least 2.59 millimoles per liter [mmol/L]). All study patients were on ongoing statin treatment with or without other lipid-lowering therapies. Average baseline LDL cholesterol levels in the randomized population were similar between the Praluent (141 mg/dL / 3.6 mmol/L) and placebo groups (142 mg/dL / 3.7 mmol/L).  Patients in the Praluent group who did not achieve their pre-specified LDL cholesterol goals with Praluent 75 mg at week 8 (2 out of 140 patients who continued treatment beyond week 12) were increased to Praluent 150 mg every two weeks at week 12.

In the ODYSSEY JAPAN trial, Praluent reduced LDL cholesterol by 63 percent at week 24 on top of stable background statin therapy, compared to a 2 percent increase in the placebo group (p less than 0.0001, ITT analysis). Patients treated with Praluent maintained their LDL cholesterol reductions for the duration of the trial. By week 52, patients in the Praluent group achieved an average LDL cholesterol of 53.4 mg/dL (1.38 mmol/L) compared to an average LDL cholesterol of 135.6 mg/dL (3.51 mmol/L) in the placebo group (ITT population).

In the trial, Praluent was generally well-tolerated with an acceptable safety profile. Frequently reported adverse events included nasopharyngitis (46 percent Praluent versus 36 percent placebo); back pain (13 percent Praluent versus 6 percent placebo); and injection site reaction (13 percent Praluent versus 4 percent placebo).

“Results from the Japanese Phase 3 trial were consistent with the findings from our global ODYSSEY program that evaluated the efficacy and safety of Praluent in patients who required further reduction of their LDL cholesterol,” said Bill Sasiela, Ph.D., VP, Program Direction, Regeneron. “Notably, in the ODYSSEY JAPAN trial, 99 percent of patients were able to effectively reach their LDL cholesterol goals as defined by the Japan Atherosclerosis Society with Praluent 75 mg Q2W and maintain these reductions for the duration of their therapy, up to 52 weeks.”

In ODYSSEY JAPAN, LDL cholesterol goals were defined according to the “Guidelines for Prevention of Atherosclerotic Cardiovascular DiseaSES 2012″ published by the Japan Atherosclerosis Society (JAS) in which goals are set according to patients’ risk of cardiovascular events. The JAS guidelines define the risk of cardiovascular events as high when the patient has a history of coronary artery disease, a history of ischemic stroke (other than cardiogenic cerebral infarction), peripheral artery disease, diabetes mellitus, and chronic kidney disease, or in the presence of several risk factors for atherosclerosis.

In Japanese Phase 2 and 3 clinical trials, adverse events were observed in 17 percent (33 of 193) of patients on Praluent 75 mg or 150 mg. The most common adverse event was injection site reactions in 22 CASes (11.4 percent).

Praluent is also approved in the United States, European Union, Canada and Mexico. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.

About Praluent
Praluent inhibits the binding of PCSK9 to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which results in lower LDL cholesterol (so-called “bad” cholesterol) levels in the blood.

In July 2015, the companies announced that Praluent was approved for use in the U.S. as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL cholesterol.

In September 2015, the European CommISSion approved the marketing authorization for Praluent. In the E.U., Praluent is approved for the treatment of adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL cholesterol goals with the maximally-tolerated statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin intolerant, or for whom a statin is contraindicated.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Important Japan Product Information
Praluent is indicated for the treatment of patients with FH or hypercholesterolemia who have high cardiovascular risk with LDL cholesterol not adequately controlled by HMG-CoA reductase inhibitors.

Precautions Related to Indications in Japan
(1)  Patients should undergo careful medical examinations, including tests confirming FH or non-FH before using Praluent.
(2)  In patients with non-FH, the use of Praluent should be considered for patients with high cardiovascular risk based on confirmed risk factors (e.g., coronary artery disease, non-cardiogenic cerebral infarction, peripheral arterial disease, diabetes mellitus, chronic kidney disease, etc.) See ‘Clinical Studies’ section.
(3)  For homozygous FH, the efficacy and safety of Praluent has not been established. Treatment with Praluent should be carefully determined, and in case of no response, treatment should be discontinued. See ‘Important Precautions (2)’ section.

Dosage and Administration in Japan
For adults, the usual dosage is 75 mg administered subcutaneously every two weeks. If there is an insufficient response, dosage can be increased to 150 mg.

Precautions Related to Dosage and Administration in Japan
(1)  Praluent should be administered in combination with HMG-CoA reductase inhibitor therapy. (The efficacy and safety of Praluent monotherapy in Japanese patients has not been established.)
(2)  When used with LDL apheresis treatment concomitantly, Praluent treatment should be scheduled following the LDL apheresis treatment.

Important Safety Information for U.S.
Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT. Before you start using PRALUENT, tell your healthcare Provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you are breastfeeding or plan to breastfeed.

Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies.

PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen face, or trouble breathing.

The most common side effects of PRALUENT include: redness, itching, swelling, or pain/tenderness at the injection site, symptoms of the common cold, and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the “Instructions for Use” that comes with Praluent.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for the full Prescribing Information.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions FOCused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic aLTErnatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron’s products, product candidates, and research and clinical programs now underway or planned, including without limitation Praluent® (alirocumab) Injection; unforeseen safety issues and possible liability resulting from the administration of products (including without limitation Praluent) and product candidates in patients; serious complications or side effects in connection with the use of Regeneron’s products and product candidates in clinical trials, such as the ODYSSEY OUTCOMES trial prospectively assessing the potential of Praluent to demonstrate cardiovascular benefit; coverage and reimbursement determinations by third-party payers, including Medicare, Medicaid, and pharmacy benefit management companies; ongoing regulatory obligations and oversight impacting Regeneron’s marketed products (such as Praluent), research and clinical programs, and business, including those relating to the eNROllment, completion, and meeting of the relevant endpoints of post-approval studies (such as the ODYSSEY OUTCOMES trial); determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s products and product candidates; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s late-stage product candidates and new indications for marketed products; competing drugs and product candidates that may be superior to Regeneron’s products and product candidates; uncertainty of market acceptance and commercial success of Regeneron’s products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron’s products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi and Bayer HealthCare LLC (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron’s filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2015 and its Form 10-Q for the quarterly period ended March 31, 2016. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. 

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

 

 

SOURCE Regeneron Pharmaceuticals, Inc.

Source: PrNewsWire All
Link: Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan

Global Autoinjectors Market, 2026 – Market Will Grow at an Annualized Growth Rate of Over 8% in the Next Ten Years – Research and Markets

DUBLIN, July 4, 2016 /PRNewswire/ —

Research and Markets has announced the addition of the “Global Autoinjectors Market, 2016 – 2026” report to their offering.

The Global Autoinjectors Market, 2016-2026′ report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution of these devices over the next decade. Starting with an overview of self-administration devices, the report elaborates on the origin / history of autoinjectors, their components and advantages offered by different categories of autoinjectors.

It also covers information on needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes that are incorporated as primary drug containers in autoinjectors.

One of the key objectives of the study is to enumerate various autoinjectors available in the market, combination products currently available / being developed and the corresponding market potential across different therapeutic areas.

Amongst other elements, the report elaborates on the following key areas:

– The current state of the market with respect to key players, routes of administration, primary drug containers, usability, indications and drugs being targeted.

– 2 X 2 matrices depicting the product competitiveness and supplier power across the growing landscape of dISPosable and reusable autoinjectors.

– Detailed CASe studies on the drugs that have been potential targets for autoinjectors.

– List of likely candidates for delivery via autoinjectors based upon their route of administration, targeted indication and dosage regime.

– Detailed company profiles of the key autoinjector manufacturers as well as emerging players that are trying to build a foothold in this industry.

– The future growth opportunities likely to drive the market in the short term and long term.

The study also FOCuSES on analyzing the existing market size and potential future growth of these drug delivery devices across different therapeutic classes, routes of administration and extent of usability. The report provides sales foreCAST for the overall autoinjectors market for the period 2016 – 2026. It takes into account the price variation that is likely to occur as a result of mass adoption and increased competition.

For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. 2015 is the base year; actual figures have been sourced and analyzed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Example Highlights

– During our research, we identified over 80 autoinjectors being developed or commercially available by more than 20 companies. Over 50 drugs as combination products have been commercialized so far; several companies such as Amgen, GSK, Sanofi and Palatin Technologies are testing their late stage pipeline drugs with autoinjectors.

– Most of the autoinjectors being developed are disposable devices, contributing a share of 62%; reusable / rechargeable / electronic autoinjectors have also emerged providing options for multiple dosing of the drugs.

– Some of the established pharmaceutical stakeholders working in this domain include BD, Bespak, Changzhou Delfu, Elcam Medical, DALI Medical Devices, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico, West Pharmaceutical Services and Ypsomed. Several new / small companies have entered with their innovative technologies and devices. Examples of such innovators include Amedra Pharmaceuticals, ChemProtect SK, Future Injection Technologies, Haselmeier AG, Kaleo Pharma, Nuance, Nemera, Oval Medical Technologies, Unilife and Xeris Pharmaceuticals.

– Developers are focusing on introducing a variety of advanced features to make these devices more user-friendly. Specific examples include push-on-skin release, one-handed operation, twist & mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek designs. Smart electronic autoinjectors are being developed featuring bluetooth connectivity, LCD screen and special software to connect the device or part of the device with computer systems to maintain injection records. Some of the devices, such as Safelia autoinjector (Nemera) and Syrina AR (Bespak), are also capable of delivering drugs with high volume and high viscosity.

– A variety of novel technologies have emerged for the development of autoinjectors. Examples of such technologies include Breeze technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft technology (Bespak), Rotaject Pressure Release technology, NIT technology, Negasai spring technology and Pushclick technology (SHL Group).

– Although autoinjectors have been in the market for over two decades, the market is still evolving. There is widespread optimism that such devices hold significant opportunity for the pharmaceutical companies; the rapidly evolving pipeline of biologics and biosimilars will act as a major driver.

– We anticipate the global autoinjectors market to grow at an annualized growth rate of over 8% in the next ten years. Launch in emerging regions such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Primary Drug Containers in Autoinjectors

5. Autoinjectors: Current Market Landscape

6. Case Studies

7. Key Players

8. Emerging Players

9. Global Autoinjectors Market Forecast, 2016 – 2026

10. Future Growth Opportunities

11. Interview Transcripts

12. Conclusion

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

– 3P Limited

– ALK-Abelló A/S

– AbbVie

– Ablynx

– Aguettant

– Allergy Therapeutics

– Alliance Healthcare

– Allozyne (Acquired by MedImmune)

– Amag Pharmaceuticals

– Amedra Pharmaceuticals (Acquired by Impax Laboratories)

– Amgen

Antares Phama

– Aptar Pharma

– Arte Corporation

– Aventis Pharma

– Bang & Olufsen Medicom

– Bayer Healthcare

Becton Dickinson & Co.

– Bespak

– Biogen Idec

– Bioprojet

– Boehringer Ingelheim

– Bristol-Myers Squibb

– Brunswick Biomedical Corporation

– Cambridge Capital Group

– Cambridge Consultants

– Celgene Corporation

– Central Texas Angel Network

– Changzhou Delfu Technology

– ChemProtect SK

– Chugai Pharmaceutical Co. Ltd

– CiToxLab

– Consort Medical

– Cytheris

– CytoDyn

– DALI Medical Devices

– Daikyo Seiko

– Disetronic

– Dr. Reddy’s Laboratories

– EMD Serono

– Elcam Medical

 – Eli Lilly

– Emergent Biosolutions

– Exsulin

– FFT Medical

– Future Injection Technologies

– Gerresheimer

– GlaxoSmithKline

– Global Pharma

– Globe Medical Tech

– Haselmeier AG

– Hemispherx Bioscience

– Hoffmann-La Roche

– Hospira

– Immune Response Biopharma

– Immunex

– Injectech

– Ionis Pharmaceuticals

– JHP Pharmaceuticals

– Janssen Biotech

– Jiangsu Delfu medical device

– Johnson & Johnson

– Kaleo (formerly known as Intelliject)

– King Pharmaceuticals

– Kisling AG

– Labrys Biologics (Acquired by Teva)

– Lincoln Medical (Acquired by Bioprojet Pharma)

– Lineage Therapeutics

– LyoGo

– MSD Animal Health

– MedPro

– Medac Pharma

– Medeca Pharma

– Medical Valley Alliance

– Merck

– Merck Serono

– Meridian Medical Technologies

– Merz Pharmaceuticals

– Mylan

– National Health Service

– Nemera

– Nipro Corporation (Acquired MGlas)

– Novartis

– Novo Nordisk

– Nuance Design

– Nuova Ompi

– Nuron Biotech

– Otsuka Pharmaceuticals

– Oval Medical Technologies

Owen Mumford

– PA Consulting Group

– PDL BioPharma

– PHC Injection Device Technologies

– Palatin Technologies

– Pfizer

– Pharma-Pen

– PhaseBio Pharmaceuticals

– Plas-Tech Engineering

– Project Pharmaceutics

– Redmile Group

– Regeneron Pharmaceuticals

– Revolutions Medical

– Roselabs Bioscience

SCHOTT AG

– SKINSORB

– Sabby Management

– Sanofi

– Sanofi Pasteur

– Santarus

– Scandinavian Health Limited Group

– School of Medicine at the University of Texas Health Science Center San Antonio

– Schreiner MediPharm

– Sciele Pharma (Now Known as Shionogi Pharma)

– Shandong Weigao Group

– SiO2 Medical Products

– SiliCycle

– Sumitomo Dainippon Pharma

– Sun Pharma

– Survival Technologies

Taisei Kako

– Takeda

– Team Consulting

– Terumo Corporation

– Teva Pharma Industries

– Texas Diabetes Institute (TDI) of the University Health System

– The Cambridge Angels

– The McNair Group

– The Medical House (TMH)

– Tonghua Dongbao Pharmaceutical

– UCB

– US Medical Instruments

– US WorldMeds

– Uman Pharma

– Unilife Corporation

– Union Medico

– Valeant Pharmaceutical International

– Vetter Pharma

– West Pharmaceutical Services

– Windgap Medical

– Xeris Pharmaceuticals

– Ypsomed Delivery Systems

– Zion Clinical Pharmacy

– medac GmbH

For more information visit http://www.researchandmarkets.com/research/cj4bdj/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets

Source: PrNewsWire All
Link: Global Autoinjectors Market, 2026 – Market Will Grow at an Annualized Growth Rate of Over 8% in the Next Ten Years – Research and Markets

Parkinson’s Diseases: World Drug Industry and Market 2016-2026

NEW YORK, July 4, 2016 /PRNewswire/ — Report DetaILS
Parkinson’s DiseaSES: World Drug Industry and Market 2016-2026 – our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses ISSues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:
– How is the Parkinson’s disease therapeutics market evolving?
– What is driving and restraining the Parkinson’s disease therapeutics market?
– How will political and regulatory factors influence the regional markets and submarkets?
– Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the foreCASt period?
– What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

SOURCE Reportlinker

Source: PrNewsWire All
Link: Parkinson’s Diseases: World Drug Industry and Market 2016-2026

Media Advisory: Command of Ontario’s Army to Change Hands

Land Force Central Area – Dept of National Defence

Land Force Central Area - Dept of National Defence

July 04, 2016 15:28 ET

TORONTO, ONTARIO–(Marketwired – July 4, 2016) – Department of National Defence

Command of 4th Canadian Division / Joint Task Force (Central) will officially change hands during a ceremony to be held at Queen’s Park in Toronto.

When: 10:30 a.m. on Wednesday, July 6, 2016.

Where: Queens’s Park, 111 Wellesley Street, Toronto. The ceremony will be held outdoors on the south side of the building.

Notes to editor / News director:

There will be a Public Affairs Officers on-site during the ceremony that will be available to answer questions. Although there will be small receptions both before and after the ceremony, these are closed to the public and media.

For more information on the 4th Canadian Division please visit:

http://www.army-armee.forces.gc.ca/en/central/index.page

https://www.flickr.com/photos/lfca_multimedia

https://www.facebook.com/4CdnDiv4DivCA

You are using an outdated browser

For a better experience using this site, please upgrade to a modern web browser.

Source: Marketwired – All
Link: Media Advisory: Command of Ontario’s Army to Change Hands

LAUNCH ANNOUNCEMENT – BLOCKCON 2017 – Global Blockchain Conference, 28 & 29 March 2017, Marina Bay Sands

Singapore, July 4, 2016 /PRNewswire/ — Today, we are pleased to announce the launch of BLOCKCON 2017, the first global Blockchain conference in Singapore, featuring Blockchain and cryptocurrency related innovation. Jointly organised by UBM Exhibition Singapore Pte Ltd and The Singapore Fintech Consortium Pte Ltd, this conference will take the stage at Marina Bay Sands Singapore on 28 & 29 March 2017.

 

Blockchain is a distributed public network that creates an immutable historical ledger of transaction in an efficient, transparent and secured way. It has the potential to revolutionize the way we look at the global finance economy as a whole, with its applications ranging from trading and payments, to security and legal ownership. It not only captures the attention of banks, but also exchanges, insurers and government who are looking into Blockchain to reshape daily operations, reduce costs and improve transparency.

In this 2-day conference, BLOCKCON 2017 will be expecting more than 1,000 global Blockchain innovators and professionals of diverse backgrounds — including regulators, entrepreneurs, investors and financial industry executives.

The engagement topics revolve around Blockchain’s rising opportunities and challenges, regulation and collaboration, as well as its application in finance and beyond. BLOCKCON 2017 will also feature a series of interactive panel discussion SESsions, fireside chats and live demos that will probe deeper into what it takes for Blockchain solutions to be successful, and how this emerging technology can be applied for data integrity, trust and accessibility.

“Blockchain has the potential to redefine numerous value chains, exchange platforms and business processes. We observe fascinating “proof of concepts” being tested and user CASes being developed not only within the financial service industry, but across other major industries and public sectors. Some of the key themes, topics and applications that are being explored are related to identity, authentication, fraud, record keeping, “smart” self-executing contracts and various forms of transfer of digital assets, value and data,” said Gerben VISSer, Co-Founder of The Singapore FinTech Consortium Pte Ltd.

“We believe BLOCKCON 2017 will provide a unique knowledge exchange platform, facilitate partnership opportunities across the Blockchain ecosystem, as well as educate financial participants and stakeholders on the potential applications,” said Paul Wan, Managing Director of UBM Exhibition Singapore Pte Ltd.

Pre-registration for BLOCKCON 2017 is now open. Be sure to take advantage of the super early registration discount here via http://blockcon.co/event-registration/  

Call for Papers (CFP) is now open. BLOCKCON is seeking ground breaking Blockchain research for next year’s conference. For more information on Call for Papers, potential speaker can submit their research via http://blockcon.co/call-for-paper/ 

Don’t miss out on hearing first-hand from the people shaping the future. We look forward to seeing you at BLOCKCON 2017. 

For more information and contact detaILS, please visit http://www.blockcon.co, follow us on Twitter, Facebook and Linkedin for our latest updates.

About UBM Exhibition Singapore Pte Ltd (www.ubmasia.com.sg)

UBM Exhibition Singapore Pte Ltd, a member of the UBM Asia group of companies, organises trade shows and conferences for a number of market sectors including child-baby-maternity products, information technology, jewellery, maritime, pulp and paper, etc. The company stages the leading events in its targeted industries across the world, attracting quality exhibitors, trade visitors, conference attendees and speakers from all over the world. These events are important business platforms where our customers can meet and network with their existing and new business partners face-to-face.

About UBM plc (www.ubm.com)

UBM plc is a leading global events-led marketing services and communications company. We help businesses do business, bringing the world’s buyers and sellers together at events, online and in print. Our 5,000 staff in more than 20 countries are organised into specialist teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.  Running over 400 events per year UBM is the second largest exhibitions organiser globally and the biggest commercial organiser in the US, mainland China, India and Malaysia.

For more information, go to http://www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news; follow@UBM for news and updates from across the businesses and selected members of UBM’s Twitterati. http://media.ubm.com/social.

About The Singapore FinTech Consortium Pte Ltd (www.singaporefintech.com)

The Singapore FinTech Consortium aims to further the development, interaction and acceleration of the FinTech ecosystem in Singapore and Southeast Asia. We foster synergies among market players, including government bodies, financial institutions, corporates, investors and innovators, who believe that technology can bring added value to the financial industry. 

Through our FinTech inCubation platform, we offer corporate incubation, research lab and venture acceleration as well as provide access to analytical tools and FinTech related resources. We believe that FinTech is a crucial infrastructure layer for the Southeast Asia region and for Singapore to maintain and strengthen its leadership in financial services.

For more information, go to www.singaporefintech.com and follow us on Twitter, Facebook and Linkedin.

For media information, please contact:

Leon Kwek
Assistant Event Manager, BLOCKCON
UBM Exhibition Singapore Pte Ltd
Tel:+65 6592 0888 ext.887
E-mail: leon.kwek@ubm.com
Website: http://www.ubmasia.com.sg

Yingyao Xie
Business Analyst, The Singapore FinTech Consortium Pte Ltd
Tel: +65 83385942
E-mail: yingyao@singaporefintech.com
Website: http://www.singaporefintech.com

Logo – http://photos.prnewswire.com/prnh/20160627/384093LOGO
Logo – http://photos.prnewswire.com/prnh/20160627/384094LOGO
Logo – http://photos.prnewswire.com/prnh/20121014/HK92339LOGO-d

SOURCE BLOCKCON

Source: PrNewsWire All
Link: LAUNCH ANNOUNCEMENT – BLOCKCON 2017 – Global Blockchain Conference, 28 & 29 March 2017, Marina Bay Sands